A Study for Patients with Advanced Kidney Cancer who are Currently on Treatment or in Follow-up for a Pembrolizumab Study (KEYNOTE-587)

Trial ID: NCT03486873


Pembrolizumab (Keytruda®) is an immunotherapy drug that is already approved for the treatment of kidney cancer in Canada. It works by targetting a molecule called PD-1 to reactivate the body’s own immune response to target and destroy cancer cells.

The purpose of this study is to assess the long-term safety and effectiveness of pembrolizumab in patients who took part in a previous pembrolizumab based study. This is called a rollover study.

The Trial:

There are 3 different phases to this study depending on where you were on your initial pembrolizumab study.

Your doctor will be able to advise you on whether this trial is right for you.

Basic Eligibility:

  • Advanced kidney cancer that cannot be removed by surgery
  • Must be enrolled or previously enrolled in a Merck-sponsored pembrolizumab study

Additional eligibility criteria will apply. Please speak to your doctor.


Find out more about this study
Hospital / Cancer CentrePrincipal InvestigatorLocationTrial Status
Hospital / Cancer CentreCross Cancer Institute Principal InvestigatorDr. Quincy Chu LocationEdmonton, AB Trial StatusRecruiting
Hospital / Cancer CentreJuravinski Cancer Centre Principal Investigator LocationHamilton, ON Trial StatusRecruiting
Hospital / Cancer CentreSunnybrook Research Institute Principal Investigator LocationToronto, ON Trial StatusRecruiting
Hospital / Cancer CentrePrincess Margaret Cancer Centre Principal InvestigatorDr. Marcus Butler LocationToronto, ON Trial StatusRecruiting
Hospital / Cancer CentreJewish General Hospital Principal InvestigatorDr. Wilson Miller LocationMontreal, QC Trial StatusRecruiting
Do NOT follow this link or you will be banned from the site!